Alert: Major Price Advance (11/29/18)-Adaptimmune Therapeutics plc (NASDAQ: ADAP).


Adaptimmune Therapeutics plc (NASDAQ: ADAP)



Major Price Advance

On 11/29/18, Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock enjoyed a major increase of 15.5%, closing at $5.95. Moreover, trading volume in this advance was above average at 138% of normal. Relative to the market the stock has been weak over the last nine months but has risen 8.6% during the last week.

Current PriceTarget Research Rating

ADAP is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.

ADAP has a current Value Trend Rating of F (Negative). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. ADAP has a poor Power Rating of 17 and a very low Appreciation Score of 8, leading to the Negative Value Trend Rating.

Rating Review

In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.

About John Lafferty 76994 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.